Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.cscpl.com | |
Market Cap | 839.94 Cr. | |
Enterprise Value(EV) | 682.86 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 18.00 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 12.74 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 26.42 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 122.04 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 1.88 | Calculated using Price: 229.30 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 3.66 Cr. | 36,630,701 Shares |
FaceValue | 10 | |
Company Profile | ||
The company is a manufacturer of specialised chemicals, such as HMDS and CMIC which are predominantly used in the pharmaceuticals industry (the Pharmaceutical Chemicals), and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields industry. The company supply its products to domestic customers and also export its products to countries including United States of America , Italy, South Korea, Germany, People's Republic of China, Japan, United Arab Emirates, Serbia, Russia, Spain, Thailand and Malaysia. |
1 Day |
|
+0.62% |
1 Week |
|
-7.23% |
1 Month |
|
-14.00% |
3 Month |
|
-23.51% |
6 Month |
|
-49.14% |
1 Year |
|
-14.26% |
2 Year |
|
-43.93% |
5 Year |
|
|
10 Year |
|
6 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 10.44 | 65.40 | 57.14 | 40.14 | 22.56 | 16.28 | |
Return on Capital Employed (%) | 13.60 | 74.02 | 64.99 | 43.37 | 29.01 | 20.85 | |
Return on Assets (%) | 4.51 | 33.03 | 31.87 | 24.50 | 17.92 | 13.92 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 27 | 54 | 97 | 146 | 354 | 417 | 436 | |
Non Curr. Liab. | 4 | 5 | 5 | 18 | 10 | 3 | 4 | |
Curr. Liab. | 32 | 39 | 71 | 62 | 40 | 78 | 68 | |
Minority Int. | ||||||||
Equity & Liab. | 63 | 97 | 173 | 226 | 404 | 498 | 507 | |
Non Curr. Assets | 26 | 32 | 42 | 53 | 119 | 122 | 143 | |
Curr. Assets | 37 | 65 | 131 | 173 | 285 | 376 | 365 | |
Misc. Exp. not W/O | ||||||||
Total Assets | 63 | 97 | 173 | 226 | 404 | 498 | 507 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 90 | 158 | 303 | 262 | 243 | 257 | 313 | |
Other Income | 0 | 0 | 2 | 4 | 5 | 9 | 13 | |
Total Income | 90 | 158 | 305 | 266 | 248 | 266 | 326 | |
Total Expenditure | -81 | -113 | -237 | -192 | -162 | -176 | -229 | |
PBIDT | 9 | 46 | 68 | 74 | 86 | 91 | 97 | |
Interest | -2 | -3 | -4 | -5 | -4 | -1 | -1 | |
Depreciation | -2 | -2 | -3 | -5 | -6 | -6 | -8 | |
Taxation | -2 | -14 | -18 | -16 | -20 | -21 | -22 | |
Exceptional Items | ||||||||
PAT | 3 | 26 | 43 | 49 | 56 | 63 | 66 | |
Adjusted EPS | 4 | 33 | 14 | 15 | 15 | 17 | 18 |
Particulars | 6 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 2 | 14 | 11 | 12 | 65 | 74 | |
Cash Fr. Inv. | -8 | -7 | -24 | -16 | -152 | -93 | |
Cash Fr. Finan. | 5 | -6 | 12 | 4 | 111 | 30 | |
Net Change | 0 | 1 | 0 | 0 | 23 | 11 | |
Cash & Cash Eqvt | 1 | 1 | 1 | 1 | 24 | 36 |
Wed, 29 Mar 2023
Closure of Trading Window Intimation of closure of Trading Window |
Tue, 21 Mar 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 |
Fri, 10 Feb 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Transcript of Earning Call held on 6th February 2023 |
Fri, 31 Mar 2023 |
|
|
|
|
|